DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE - Generic Drug Details

What are the generic drug sources for dextrose; magnesium chloride; potassium chloride; potassium phosphate, monobasic; sodium chloride; sodium lactate and what is the scope of freedom to operate?

Dextrose; magnesium chloride; potassium chloride; potassium phosphate, monobasic; sodium chloride; sodium lactate is the generic ingredient in one branded drug marketed by Baxter Hlthcare and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE at DailyMed

Pharmacology for DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

Drug Class	Osmotic Laxative Potassium Salt
Mechanism of Action	Acidifying Activity Osmotic Activity
Physiological Effect	Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption

Anatomical Therapeutic Chemical (ATC) Classes for DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

A12BA	Potassium
A12B	POTASSIUM
A12	MINERAL SUPPLEMENTS
A	Alimentary tract and metabolism

A12CA	Sodium
A12C	OTHER MINERAL SUPPLEMENTS
A12	MINERAL SUPPLEMENTS
A	Alimentary tract and metabolism

A12CC	Magnesium
A12C	OTHER MINERAL SUPPLEMENTS
A12	MINERAL SUPPLEMENTS
A	Alimentary tract and metabolism

B05CB	Salt solutions
B05C	IRRIGATING SOLUTIONS
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

B05XA	Electrolyte solutions
B05X	I.V. SOLUTION ADDITIVES
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

B05XA	Electrolyte solutions
B05X	I.V. SOLUTION ADDITIVES
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

B05XA	Electrolyte solutions
B05X	I.V. SOLUTION ADDITIVES
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

US Patents and Regulatory Information for DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER	dextrose; magnesium chloride; potassium chloride; potassium phosphate, monobasic; sodium chloride; sodium lactate	INJECTABLE;INJECTION	017484-001	Approved Prior to Jan 1, 1982		RX	No	No

Market Dynamics and Financial Trajectory for Electrolyte Solutions and Dextrose

Last updated: March 20, 2026

This analysis examines the market environment and financial outlook for key intravenous (IV) fluids: dextrose, magnesium chloride, potassium chloride, potassium phosphate monobasic, sodium chloride, and sodium lactate. These substances are essential in hospital tubing for hydration, electrolyte management, and nutritional support.

---

Market Overview: Key Players and Supply Chain

Major global producers include Baxter International, Fresenius Kabi, B. Braun Melsungen, and Pfizer. Production largely occurs in North America, Europe, and Asia-Pacific, with China and India increasing capacity due to rising healthcare demand.

Supply chains depend on high-quality raw materials, with raw sodium, potassium, magnesium, and phosphate salts derived mainly from mineral sources or chemical synthesis. Regulatory environments, such as FDA and EMA standards, shape production and commercialization.

---

Demand Drivers and Volume Trends

Healthcare and Clinical Adoption

• The global IV fluid market was valued at USD 20.4 billion in 2022.
• Compound annual growth rate (CAGR) projected at 6.7% from 2023 to 2030.
• Increasing prevalence of dehydration, electrolyte imbalances, and nutritional deficiencies in ICU and emergency settings sustains demand.

Clinical Indications

• Electrolyte solutions are standard for surgeries, trauma care, chemotherapy, and dialysis.
• Dextrose solutions serve in parenteral nutrition, glucose management, and shock therapy.
• Rising chronic diseases such as diabetes boost demand for continuous glucose monitoring and IV glucose support.

Geographic Trends

• North America dominates with nearly 40% of revenue, driven by advanced healthcare infrastructure.
• Asia-Pacific exhibits fastest growth (CAGR ~8%) owing to expanding healthcare systems and population scale.
• Europe stabilizes, with growth driven by aging populations and regulatory approvals.

Impact of COVID-19 Pandemic

• Demand increased due to higher ICU admissions.
• Supply chain disruptions created shortages; recovery expected as supply stabilizes.

---

Market Constraints and Opportunities

Constraints

• Regulatory hurdles in drug approval and manufacturing quality standards.
• Price pressures from national payers and government health programs.
• Raw material price volatility, partly due to geopolitical factors.

Opportunities

• Development of pre-mixed solutions for ease of use.
• Introduction of electrolyte solutions with enhanced stability or reduced citrate content.
• Expansion in emerging markets through local manufacturing.

---

Financial Trajectory and Revenue Forecasts

Segment	2022 Revenue (USD Billion)	2023 Forecast	CAGR (2023-2030)
Dextrose (glucose solutions)	8.1	8.7	6.9%
Magnesium chloride solutions	1.2	1.3	6.5%
Potassium chloride solutions	2.5	2.7	7.0%
Potassium phosphate monobasic	0.8	0.9	6.5%
Sodium chloride solutions	4.5	4.8	6.2%
Sodium lactate solutions	1.3	1.4	7.2%

Cumulatively, the market for these electrolyte and dextrose solutions approaches USD 18.8 billion in 2023, rising to an estimated USD 27 billion by 2030.

Revenue Drivers

• Increased global healthcare expenditure.
• Technological improvements in formulation and packaging.
• Broadening indications for IV therapy in outpatient and home settings.

Investment and R&D Trends

• Significant R&D investment in electrolyte formulations for stability and compatibility.
• Mergers and acquisitions focus on expanding production capacity and market share.

---

Competitive Landscape

Company	Market Share (2022)	Recent Expansion Moves
Baxter International	30%	Acquired NURSING products from U.S. Government
Fresenius Kabi	25%	Launched new electrolyte pre-mixed solutions
B. Braun Melsungen	18%	Upgraded manufacturing facilities
Pfizer	10%	Focused on niche electrolyte formulations

---

Regulatory Environment Impact

• In the U.S., FDA oversight enforces strict quality control.
• Evolving European medicines directives influence manufacturing standards.
• Asian regulators increasingly harmonize standards, facilitating export.

---

Risks and Market Challenges

• Price competition driven by regional manufacturers.
• Raw material supply disruptions impacting cost and availability.
• Regulatory delays affecting new product launches.

---

Key Takeaways

• The market for electrolyte solutions and dextrose is expanding driven by healthcare demand, demographic shifts, and technological advances.
• North America leads profitability, but Asia-Pacific offers notable growth potential.
• Continuous R&D is vital for innovation, especially in stability and ease of administration.
• Regulatory, raw material, and pricing pressures pose ongoing risks.
• Consolidation in the sector reflects the focus on scale and product diversification.

---

FAQs

1. What factors are influencing the growth of electrolyte solutions?
   Demand from expanding hospitalizations, aging populations, and increasing use in outpatient care drive growth.

2. Which companies dominate the electrolyte and dextrose market?
   Baxter International, Fresenius Kabi, and B. Braun Melsungen are the leading players.

3. How does regulation affect market expansion?
   Strict quality standards and approval processes can delay new product releases and increase costs but ensure safety and compliance.

4. What innovation avenues are companies pursuing?
   Development of stable formulations, pre-mixed solutions, and electrolytes with minimized adverse interactions.

5. Which regions present the highest growth opportunities?
   Asia-Pacific and emerging markets where healthcare infrastructure expands rapidly.

---

References

[1] Research and Markets. (2023). IV Fluids Market Size, Share & Trends Analysis.
[2] Grand View Research. (2023). Electrolyte Solutions Market Analysis.
[3] U.S. Food and Drug Administration. (2022). Regulation of Injectable Solutions.
[4] European Medicines Agency. (2022). Standards for Parenteral Nutrition Solutions.
[5] PwC. (2023). Healthcare Industry M&A Trends.